OncoMatch/Clinical Trials/NCT06922539
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Is NCT06922539 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Fenretinide for small cell lung cancer.
Treatment: Fenretinide — This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have relapsed or refractory disease to prior treatment with platinum-based chemotherapy ± immunotherapy.
Cannot have received: investigational agent
Patients who are receiving any other investigational agents.
Lab requirements
Blood counts
Patients must have normal organ and marrow function.
Kidney function
Patients must have normal organ and marrow function.
Liver function
Patients must have normal organ and marrow function.
Patients must have normal organ and marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06922539 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages